Subscribe

FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma

Web Exclusives - FDA Approvals, Multiple Myeloma, In the News

On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review.

This approval was based on data from the open-label, randomized, phase 3 CASSIOPEIA clinical trial, which compared induction and consolidation treatment with daratumumab plus bortezomib, thalidomide, and dexamethasone (DVTd) versus bortezomib, thalidomide, and dexamethasone (VTd) in newly diagnosed patients with multiple myeloma who were candidates for ASCT.

Results showed that the addition of daratumumab to VTd led to a 53% reduction in the risk of progression or death compared with VTd alone (hazard ratio, 0.47; 95% confidence interval, 0.33-0.67; P <.0001). The stringent complete response rate 100 days post-ASCT was 28.9% in the DVTd arm versus 20.3% in the VTd arm. At a median follow-up of 18.8 months, the median progression-free survival had not been reached in either arm.

The most common (≥20%) adverse reactions in patients who received DVTd were infusion reactions, peripheral sensory neuropathy, constipation, asthenia, nausea, peripheral edema, neutropenia, thrombocytopenia, pyrexia, and paresthesia.

The recommended daratumumab dose is 16 mg/kg of actual body weight.

Related Items
FDA Approvals of Brand-Name Prescription Drugs, January 1, 2019, Through June 15, 2020
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Imbruvica (Ibrutinib) Receives Expanded Indication, in Combination with Rituximab, as First-Line Treatment for Chronic Lymphocytic Leukemia
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Mayzent (Siponimod) Approved for Relapsing Forms of Multiple Sclerosis, Including Active Secondary Progressive Disease
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangio­carcinoma with FGFR2 Biomarker
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Last modified: September 30, 2019
Copyright © Engage Healthcare Communications, LLC. All rights reserved.